Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA3 | O75311 | 1/20 | 0.34 |
| ▸ | GLRB | P48167 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5004491 | 0.84 | NR1D1 (0.34) | ALDH1A1NR1D1 | |
| SCHEMBL2769995 | 0.80 | ALDH1A1 (0.38) | ALDH1A1KMT2ATSHRSMN1; SMN2HSP90AB1 | |
| SCHEMBL14259370 | 0.75 | KDM4E (0.35) | ALDH1A1KMT2A | |
| SCHEMBL7902881 | 0.75 | LTB4R (0.44) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7908882 | 0.72 | ALDH1A1 (0.36) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7902880 | 0.69 | ALDH1A1 (0.44) | ALDH1A1KMT2ASMN1; SMN2NR1D1 | |
| SCHEMBL5004256 | 0.67 | GABRA5 (0.37) | ALDH1A1NR1D1 | |
| SCHEMBL15895187 | 0.67 | GLRA3 (0.39) | GLRA3GLRBALDH1A1KMT2A | |
| SCHEMBL18674465 | 0.66 | EGLN1 (0.36) | TSHR | |
| SCHEMBL10958880 | 0.65 | NR1D1 (0.51) | ALDH1A1KMT2ASMN1; SMN2HSP90AB1NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1152010-B1 | Oligonucleotide labeling reactants and their use | WALLAC OY (FI) | 2010-04-21 | — | — | EP | disclosed |
| US-6949639-B1 | Oligonucleotide labeling reactants and their use | WALLAC OY (FI) | 2005-09-27 | — | — | US | disclosed |
| US-20040260080-A1 | Oligonucleotide labeling reactants and their use | HOVINEN JARI (FI) | 2004-12-23 | — | — | US | disclosed |
| EP-1152010-A2 | Oligonucleotide labeling reactants and their use | WALLAC OY (FI) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260080-A1 | Oligonucleotide labeling reactants and their use | SSU72, LIG4, NSUN2 | GLRA3 2544/4885GLRB 648/4885ALDH1A1 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.